A Controlled Study to Determine the Efficacy and Safety of CL-108 5 mg for Acute Pain and the Prevention of OINV

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

349 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-08-02

Study Completion Date

2018-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To determine the analgesic efficacy of CL-108 5 mg by comparison with placebo and the anti-emetic efficacy of CL-108 5 mg by comparison with hydrocodone 5 mg/acetaminophen 325 mg.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Acute Pain and Opioid-Induced Nausea and Vomiting (OINV)

NCT02462811

Pain Nausea Vomiting

COMPLETED PHASE3

Phase III Study of the Safety and Efficacy of Cl-108 in the Treatment of Moderate to Severe Pain

NCT01780428

Pain Nausea Vomiting

COMPLETED PHASE3

Efficacy and Safety of Hydromorphone Hydrochloride Extended-Release Compared to Placebo in Subjects With Persistent Pain

NCT00365898

Chronic Non-Malignant Pain

TERMINATED PHASE3

A Four-Period, Four-Treatment, Four-Way Relative Bioavailability Study of CL-108 Under Fed and Fasted Conditions

NCT02465866

Healthy

COMPLETED PHASE1

Protocolized vs Discretionary Use of Opioids in Acute Pain

NCT00825370

Pain

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Adult patients with moderate or severe pain after bunionectomy will be randomized to CL-108 5 mg (hydrocodone 5 mg/acetaminophen 325 mg/ promethazine 12.5 mg), hydrocodone 5 mg/ acetaminophen 325 mg, or placebo under double-blind conditions. Over 48 hours they will use the assigned study medication and assess pain intensity, nausea, and vomiting. Uses of supplementary analgesic and antiemetic medications will be documented. Patient responses and adverse effects will also be documented during the 5-day outpatient period, too.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain Nausea Vomiting

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CL-108 5 mg

Hydrocodone 5 mg/APAP 325 mg/promethazine 12.5 mg (CL-108 5 mg) bi-layered tablet

Group Type EXPERIMENTAL

CL-108 5 mg

Intervention Type DRUG

hydrocodone 5 mg/APAP 325 mg/promethazine 12.5 mg

Norco

hydrocodone 5 mg/APAP 325 mg

Group Type ACTIVE_COMPARATOR

Norco

Intervention Type DRUG

hydrocodone 5 mg/APAP 325 mg

Placebo

Placebo 0 mg matching CL-108

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo matching CL-108

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CL-108 5 mg

hydrocodone 5 mg/APAP 325 mg/promethazine 12.5 mg

Intervention Type DRUG

Norco

hydrocodone 5 mg/APAP 325 mg

Intervention Type DRUG

Placebo

Placebo matching CL-108

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

hydrocodone bitartrate/ acetaminophen/ promethazine hydrochloride hydrocodone bitartrate/ acetaminophen Matching Placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Informed consent: Signed informed consent form obtained at screening prior to any procedures being performed.
* Gender: Male or non-pregnant and non-lactating female.
* Age: 18 years or older at time of consent.
* Foot condition: Primary unilateral first metatarsal bunionectomy (osteotomy and internal fixation) with no additional collateral procedures.
* Pain Severity: Presence of moderate or severe pain on a categorical pain intensity scale at Baseline
* Pain Confirmation: On the 0-10 numerical pain intensity scale at Baseline.
* Diary Completion: Be willing and able to record safety and efficacy ratings in the Diaries.
* Safe Transportation Home: Patient must have arrangements for transportation home from the research center accompanied by a responsible adult.

Exclusion Criteria

* Medical condition: Presence of a serious medical condition, intolerance to NSAIDs, or any other medical condition which, in the opinion of the Investigator, makes the patient unsuitable for participation.
* Infection: Acute infection of the surgical site at the time of surgery that could confound post-surgical evaluation.
* Drug Allergy: History of hypersensitivity to an opioid drug (such as hydrocodone), promethazine, acetaminophen, NSAID (such as ibuprofen or aspirin), midazolam, propofol, mepivacaine, ropivacaine or ketorolac.
* Confounding and Contraindicated Drugs: Other than protocol-permitted medications administered pre-operatively or during surgery: use within 14 days before or during the surgical procedure of any systemic corticosteroid or use within 24 hours or during the surgical procedure of any confounding prescription or non-prescription drug or any drug contraindicated with hydrocodone, acetaminophen, or promethazine. \[Note: Antibiotic for endocarditis prophylaxis (except if known to cause nausea) and aspirin (ASA) ≤ 325 mg for cardiovascular prophylaxis are permitted during the study.\] History of consuming more than 2 alcoholic drinks per day every day for the last month or a positive urine test for opiates, benzodiazepines, barbiturates, tetrahydrocannabinol, methamphetamines, cocaine, oxycodone, cotinine at screening or the morning of surgery will exclude the patient from the trial.
* Investigational Drug Use: Use of an investigational drug within the past 30 days.
* Participated in Study: Previous participation in this study.
* Pregnancy, Lactation: Women who are pregnant or lactating.
* Compliance: Inability to swallow capsules whole.
* Participant relationship: Employee at the research center, employee of the Principal Investigator, Sub-Investigators, or sponsor or relative of the Investigator, Sub-Investigators or research staff who is involved in this study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No